Results 331 to 340 of about 1,185,716 (346)
Some of the next articles are maybe not open access.
Cutaneous manifestations in COVID‐19: a first perspective
Journal of the European Academy of Dermatology and Venereology, 2020In December 2019 unexplained pneumonia cases were initially reported in Wuhan, China. The pathogen, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was isolated from lower respiratory tract samples of infected ...
S. Recalcati
semanticscholar +1 more source
Cutaneous and Ocular Toxicology, 2022
Introduction The therapeutic use of humanised monoclonal programmed cell death 1 (PD-1) (pembrolizumab, and nivolumab) and programmed cell death ligand-1 (PD-L1) (atezolizumab, avelumab, durvalumab) immune checkpoint inhibitors (ICPi) as potent ...
Maitry Bhardwaj +2 more
semanticscholar +1 more source
Introduction The therapeutic use of humanised monoclonal programmed cell death 1 (PD-1) (pembrolizumab, and nivolumab) and programmed cell death ligand-1 (PD-L1) (atezolizumab, avelumab, durvalumab) immune checkpoint inhibitors (ICPi) as potent ...
Maitry Bhardwaj +2 more
semanticscholar +1 more source
Seminars in Respiratory and Critical Care Medicine, 2020
Sarcoidosis is a chronic, multisystem, inflammatory disorder of unknown etiology that is characterized by noncaseating granulomas that impair normal organ functioning. Sarcoidosis predominantly affects the lungs, but the skin is often cited as the second
A. Caplan, M. Rosenbach, S. Imadojemu
semanticscholar +1 more source
Sarcoidosis is a chronic, multisystem, inflammatory disorder of unknown etiology that is characterized by noncaseating granulomas that impair normal organ functioning. Sarcoidosis predominantly affects the lungs, but the skin is often cited as the second
A. Caplan, M. Rosenbach, S. Imadojemu
semanticscholar +1 more source
Journal of Cutaneous Medicine and Surgery, 2020
Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and subsequent elimination of cancer cells. However, they can also lead to immune
A. Muntyanu +4 more
semanticscholar +1 more source
Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and subsequent elimination of cancer cells. However, they can also lead to immune
A. Muntyanu +4 more
semanticscholar +1 more source
The Rapid Rise in Cutaneous Melanoma Diagnoses.
New England Journal of Medicine, 2021H. Welch, Benjamin L. Mazer, A. Adamson
semanticscholar +1 more source